| dc.contributor.author | Yerlioğlu, Dilay | |
| dc.date.accessioned | 2021-03-03T21:05:03Z | |
| dc.date.available | 2021-03-03T21:05:03Z | |
| dc.date.issued | 2018 | |
| dc.identifier.citation | Yerlioğlu D., "Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on infliximab", Journal of Crohn's and Colitis, cilt.13, sa.1, ss.304-305, 2018 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_5d4eca69-d6c0-4a61-a1f5-98380459599b | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/65341 | |
| dc.identifier.uri | https://academic.oup.com/ecco-jcc/article/13/Supplement_1/S304/5300504 | |
| dc.identifier.uri | https://doi.org/10.1093/ecco-jcc/jjy222.517 | |
| dc.description.abstract | Treat to target strategy has been proposed in adult IBD to improve Quality of Life, symptoms and to treat inflammation. There are little data in the paediatric population for this approach. The aim of this study was to look if set goals (reduced PCDAI/PUCAI and Mayo/SES-CD) were achieved. | |
| dc.language.iso | eng | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.title | Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on infliximab | |
| dc.type | Makale | |
| dc.relation.journal | Journal of Crohn's and Colitis | |
| dc.contributor.department | University College London , Great Ormond St Hospital , Paediatrics | |
| dc.identifier.volume | 13 | |
| dc.identifier.issue | 1 | |
| dc.identifier.startpage | 304 | |
| dc.identifier.endpage | 305 | |
| dc.contributor.firstauthorID | 2258203 | |
